



Epichem Awarded \$200K WasteSorted e-Waste Grant

22 January 2021 – Perth, Australia: PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to announce that its wholly owned subsidiary, Epichem Pty Ltd, has been awarded a \$200,000 WasteSorted e-Waste Grant from the Western Australian Government New Industries Fund.

The grant funding will see Epichem use Oxidative Hydrothermal Dissolution technology to convert e-waste into useful end products, recover valuable metals and produce useful high value chemicals.

The research and development program will support a new and innovative solution to process collected e-waste and reduce the amount of e-waste ending up in landfill.

The WasteSorted e-Waste grants support the WA Waste Avoidance and Resource Recovery Strategy 2030 objectives - to avoid waste, recover more value and resources from waste and protect the environment from the impacts of waste.

The \$16.7 million New Industries Fund was established to support and accelerate new and emerging businesses to diversify the WA economy and create new jobs.

Epichem's CEO, Mr Colin La Galia said, "We are delighted to be awarded this grant and excited about the opportunity it presents. We are optimistic about what we can achieve with our dedicated team of chemists using this novel, innovative and disruptive technology.

"The technology has the potential to deliver significant benefits across a range of industries; supporting the economy and positively impacting the environment," added Mr. La Galia.

PharmAust Executive Chairman, Dr Roger Aston stated, "This is a potential low cost but high benefit very scalable disruptive business that may have multiple applications and customers."

This announcement is authorised by the Board.

Enquiries:

Mr Colin La Galia
CEO Epichem
Tel: 08 6167 520
colin.lagaliam@epichem.com.au

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

About Epichem:

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in over 40 countries worldwide for over 17 years. Epichem has newly constructed purpose-built, state-of-the-art laboratories and has world class equipment and expertise in synthetic and medicinal chemistry to support drug discovery projects, and for the cost-effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards. Epichem is the winner of the WA Industry Export Award 2019 for International Health, the 2020 Inspiring Story of Celebrating Remarkable Resilience Nomination for WA for the Australian Export and Investment Awards and the 2020 GHP Biotechnology Award winner for Most Innovative Chemistry Service Provider – Australia and Best in Organic Chemistry Solutions 2020. Epichem generated Aus\$3.5M in revenues in the 2020 FY. For more information, visit www.epichem.com.au

About PharmAust (PAA):

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials

About New Industries Fund

The New Industries Fund was announced in November 2017 as a \$16.7 million fund over 4 years that will support and accelerate new and emerging businesses to diversify the Western Australian economy and create new jobs and industries. For more information visit <https://www.wa.gov.au/organisation/department-of-jobs-tourism-science-and-innovation/new-industries-fund>